[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ankylosing-spondylitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ankylosing-spondylitis":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,51,91,116,141,165,186,208,239,261,286,310,337,373,400,421,446,475,497,519,547,570,599,627,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100585663","real-world-study-on-secukinumab-effectiveness-in-biologic-nave-ankylosing-spondylitis-as-patients-in-korea-100585663",false,"NCT06905288","Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea","ONSET","Inclusion Criteria:\n\n1. Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria\n2. Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4\n3. Subjects who have never used TNFi, JAKi, or IL-17i drugs before\n4. Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety\n5. Subjects who have a time of less than 5 years since AS diagnosis\n6. Subjects who are above the age of 18 years and below 40years old\n7. Subjects who give informed consent form to participate in the study\n\nExclusion Criteria:\n\n1. Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)\n2. Subjects who have congenital\u002Ftraumatic spinal deformities\n3. Subjects currently enrolled in other clinical studies\n4. Subjects who have any contraindications to secukinumab treatment","ALL","18 Years","40 Years",{"count":22,"type":23},70,"ESTIMATED","OBSERVATIONAL","This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.",[27],"Ankylosing Spondylitis",[29,27,30,31,32,33,34,35,36,37],"Secukinumab","Biologic Naive","Real World Study","Korea","Rheumatology","AS Research","Rheumatic Disease","Biologics","Clinical Effectiveness","RECRUITING","2026-08-14",{"date":41,"type":42},"2026-08-18","ACTUAL",{"date":44,"type":42},"2025-04-02",{"date":46,"type":23},"2026-12-31",{"name":48,"class":49},"Novartis Pharmaceuticals","INDUSTRY",3,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":75,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100550785","phase-2-fecal-microbiota-transplantation-in-axial-spondyloarthritis-100550785","NCT06451588","Fecal Microbiota Transplantation in Axial Spondyloarthritis","Donor Versus Autologous Fecal Microbiota Transplantation for Axial Spondyloarthritis: a Double Blind, Placebo-Controlled, Randomized Trial","MicroSpA","Inclusion Criteria:\n\n* Axial Spondyloarthritis according to the ASAS classification criteria\n* Active disease defined as ASDAS ≥2.1 with elevated CRP ≥3 OR active inflammation on MRI within the last 3 months\n* Onset of axial SpA within last 10 years\n* Unsatisfactory relief of NSAIDs\n* On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months OR without immunomodulatory treatment last 3 months\n\nExclusion Criteria:\n\n* Planned dose adjustment or change in immunomodulatory treatment the next 90 days\n* Disease or disorder with life expectancy of ≤5 years\n* Severe immune deficiency (acquired, congenital og du to medication)\n* Previous treatment with FMT\n* Regular use of opioids with the exception of codeine and tramadol\n* Any specific diagnosis that could explain or contribute to the patients back pain (e.g. tumor, fracture, infection or degenerative disease)\n* Inflammatory spinal disease other than axSpA\n* Severe psychiatric disorder, alcohol- or drug abuse\n* Active inflammatory bowel disease\n* Microscopic colitis, diverticulitis or ileus\n* Active psoriasis\n* Fibromyalgia\n* Abdominal surgery excluding appendectomy, cholecystectomy, hysterectomy, caesarian section, sapling-ooforectomy and hernia surgery\n* Malignant disease excluding basalioma and melanoma stage 1\n* Conditions with expected necessary treatment with antibiotics during the study period, e.g. periodontitis end ischemic digital ulcers\n* Treatment with antibiotics 12 weeks prior to study entry\n* Pregnancy, lactation or planned pregnancy within the next 3 months\n* Contraindications for rectal catheter insertion\n* Planned rehabilitation program the next 90 days\n* Limited ability to comply with protocol requirements, including biobank participation","65 Years",{"count":61,"type":23},99,"INTERVENTIONAL",[64],"PHASE2","Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints.\n\nIt has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy.\n\nThe goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy.\n\nThe main questions it aims to answer are:\n\n* Can FMT reduce disease activity in axial SpA?\n* Can FMT alleviate pain and reduce fatigue in axial SpA?\n* Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT?\n\nParticipants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.",[67,27,68,69,70,71,72,73,74],"Axial Spondyloarthritis","Dysbiosis","Spondyloarthritis","Spondylitis","Arthritis","Musculoskeletal Diseases","Spinal Disease","Joint Diseases",[67,76,77,78,79,80],"Microbiome","Fecal Microbiota Transplantation","Microbiota","FMT","RCT","2026-08-11",{"date":39,"type":42},{"date":84,"type":42},"2024-06-01",{"date":86,"type":23},"2027-11",{"name":88,"class":89},"University Hospital of North Norway","OTHER",1,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":24,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100650700","15-hydroxyprostaglandin-dehydrogenase-in-osteoarthritis-and-ankylosing-spondylitis-100650700","NCT07751263","15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis","15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis: Associations With Clinical and Musculoskeletal Ultrasound Features.","HPGD-OA-AS-US","Inclusion Criteria:\n\n* Inclusion criteria\n\n  * Adults aged 18 years or older. AxSpA group Patients diagnosed as ankylosing spondylitis according to ASAS criteria . R OA group\n\n    * Adults with osteoarthritis Diagnosed according to the American College of Rheumatology classification criteria.\\[8\\]R ACR Clinical classification criteria for Osteoarthritis of the hip ACR Clinical classification criteria for Osteoarthritis of the knee ACR Clinical classification criteria for Osteoarthritis of the hand Control group Age- and sex-matched healthy controls.\n\nExclusion Criteria:\n\n* • Other inflammatory arthritides such as psoriatic arthritis, gout, or SLE-related arthritis.\n\n  * Septic arthritis or suspected joint infection.\n  * Recent intra-articular steroid injection if it may influence biomarker results.\n  * Any major systemic illness likely to affect biomarker measurement or ultrasound interpretation.\n  * Patients received certain drugs as non-steroidal anti-inflammatory drugs (NSAIDs)",true,{"count":101,"type":23},51,"1 Year","To evaluate serum and synovial fluid 15-PGDH levels in patients with osteoarthritis and ankylosing spondylitis and determine their associations with clinical and musculoskeletal ultrasound features.\n\nTo compare 15-PGDH concentrations among patients with knee osteoarthritis, and ankylosing spondylitis with knee effusion\n\nTo evaluate whether serum 15-PGDH reflects intra-articular 15-PGDH concentrations.\n\nAnalysis the level of 15-PGDH in relation to disease activity and severity of both diseases.",[105,27],"Osteoarthritis","NOT_YET_RECRUITING","2026-08-03",{"date":109,"type":42},"2026-08-07",{"date":111,"type":23},"2026-08-02",{"date":113,"type":23},"2028-08-02",{"name":115,"class":89},"Assiut University",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100649561","a-study-to-assess-the-safety-of-subcutaneous-secukinumab-for-treatment-in-adult-indian-participants-with-axial-spondyloarthritis-axspa-ankylosing-spondylitis-as-and-non-radiographic-axial-spondyloarthritis-nr-axspa-100649561","NCT07737730","A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)","A Prospective, Observational, Multicentre Study to Assess the Safety of Subcutaneous Secukinumab 150 mg Solution for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Over a Period of 16 Weeks","Inclusion criteria:\n\n1. Participant or his\u002Fher legally acceptable representative (LAR) who are willing to voluntarily provide signed informed consent for participation in the study.\n2. Adult male or female participants (≥18 years) diagnosed with axSpA, AS, and nr-axSpA.\n\nExclusion criteria:\n\n1. Participants who meet any contraindication outlined in the current Prescribing Information (PI)\u002FPackage Insert for secukinumab at the time of screening.\n2. Pregnant or lactating women.\n3. Any surgical and\u002For medical condition, which in the opinion of the treating physician, may place the participant at higher risk of his\u002Fher participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.","100 Years",{"count":125,"type":23},60,"The aim of this study is to assess the safety of secukinumab in Indian adult participants with axSpA, AS, and nr-axSpA over a 16-week treatment period. The present study is being undertaken to fulfill the Post Marketing Surveillance (PMS) mandate by the Health Authority (HA) to evaluate the safety of secukinumab solution for injection administered subcutaneously in a pre-filled pen in the indicated population under real-world clinical practice conditions.",[67,27,128],"Non-Radiographic Axial Spondyloarthritis",[130,131,128,29,132],"Axial Spondyloarthritis,","Ankylosing Spondylitis,","Quality of Life","2026-07-27",{"date":135,"type":42},"2026-07-30",{"date":137,"type":23},"2026-09-30",{"date":139,"type":23},"2027-04-30",{"name":48,"class":49},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":99,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100641821","evaluation-of-serum-il-41-level-in-patients-with-ankylosing-spondylitis-and-psoriatic-arthritis-100641821","NCT07648836","Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis","Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis and Their Association With Inflammatory Markers and Disease Activity","Inclusion Criteria:\n\n* patients diagnosed with ankylosing spondylitis (AS)and psoriatic arthritis (PsA), in addition to age- and sex-matched healthy controls.\n\nAS diagnosed according to the modified New York criteria, while PsA was diagnosed based on the CASPAR criteria.\n\nExclusion Criteria:\n\nPatients under the age of 18 years, patients with other autoimmune diseases, diabetes mellitus, chronic kidney or liver disease, active infection, or malignancy were excluded to avoid confounding factors affecting inflammatory markers.",{"count":149,"type":23},90,"Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic inflammatory diseases within the spectrum of spondyloarthritis, characterized by immune-mediated inflammation and progressive functional impairment. Meteorin-like protein (Metrnl) is a novel adipomyokine with potential immunomodulatory and anti-inflammatory properties; however, its role in spondyloarthritis remains incompletely understood. This study aims to evaluate serum Metrnl levels in patients with PsA and AS compared with healthy controls and to investigate their association with disease activity, inflammatory markers, and clinical manifestations. The findings may provide insights into the potential role of Metrnl as a biomarker of disease activity and inflammation in spondyloarthritis.",[27,152],"Psoriasis",[154,155,156],"Ankylosing spondylitis","psoriasis","biomarker","2026-07-19",{"date":159,"type":42},"2026-07-21",{"date":161,"type":23},"2026-10-01",{"date":163,"type":23},"2026-12-30",{"name":115,"class":89},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":90},"100642645","assessment-of-peripheral-neuropathy-in-ankylosing-spondylitis-100642645","NCT07641920","Assessment of Peripheral Neuropathy in Ankylosing Spondylitis","Assessment of Peripheral Neuropathy in Ankylosing Spondylitis and Its Correlation With, Central Sensitization, Disease Activity and Quality of Life","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* Diagnosis of ankylosing spondylitis according to the modified New York criteria (6).\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Patients under the age of 18 years.\n* Patients with definite diagnosis for any other systemic autoimmune disorders.\n* Diabetes mellitus\n* Chronic renal or hepatic disease\n* Alcohol abuse or drug-induced neuropathy\n* Known neurological disorders affecting peripheral nerves",{"count":173,"type":23},45,"investigators hypothesized that peripheral neuropathy in ankylosing spondylitis is associated with higher disease activity, greater central sensitization, worse functional impairment, and poorer quality of life.",[27,176],"Peripheral Neuropathies",[27,132,178],"Peripheral Neuropathy","2026-06-10",{"date":181,"type":42},"2026-06-12",{"date":183,"type":23},"2026-06-30",{"date":161,"type":23},{"name":115,"class":89},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":193,"targetDuration":4,"studyType":62,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":90},"100643142","phase-1-safety-and-efficacy-of-allogeneic-bone-marrow-mscs-in-ankylosing-spondylitis-100643142","NCT07632599","Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis","An Early Exploratory Clinical Study on the Safety and Preliminary Efficacy of Allogeneic Human Bone Marrow Mesenchymal Stem Cells in Patients With Ankylosing Spondylitis","Inclusion Criteria:\n\n* Meet the diagnostic criteria for ankylosing spondylitis (AS)\n* Age 18 to 40 years\n* Must be able to understand and communicate with the investigator, comply with study requirements, and provide signed and dated informed consent before any study assessments are performed\n* Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) total score ≥ 4 (0-10 scale), and total back pain measured by VAS ≥ 40 mm (0-100 mm)\n* CRP or ESR elevated ≥ 1.5 times the upper limit of normal\n* Patients taking methotrexate (≤ 25 mg\u002Fweek) or sulfasalazine (≤ 3 g\u002Fday) are permitted to continue these medications, provided they have been used for at least 3 months and maintained at a stable dose for at least 4 weeks prior to randomization. Patients taking methotrexate must maintain stable folic acid supplementation prior to randomization\n* Patients taking DMARDs other than methotrexate and sulfasalazine must discontinue them at least 4 weeks prior to randomization\n* No prior use of any form of biologics within 6 months\n* Spinal X-ray must rule out complete rigid ankylosis\n\nExclusion Criteria:\n\n* Known allergy to any component of the study drug (primarily bone marrow mesenchymal stem cells; excipients include dimethyl sulfoxide, human albumin, etc.)\n* Current evidence of infection or malignancy as shown by chest X-ray or MRI within 3 months prior to screening\n* Currently using potent opioid analgesics\n* Received any intra-articular injection therapy (e.g., corticosteroids) within 4 weeks prior to randomization\n* Received any intramuscular corticosteroid injection within 2 weeks prior to randomization\n* Received traditional Chinese medicine treatment for AS within 4 weeks prior to randomization\n* Pregnant or breastfeeding women\n* Presence of underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious, or gastrointestinal disease that, in the investigator's opinion, would place the patient at unacceptable risk if treated with immunomodulatory agents\n* Significant health problem or disease including (but not limited to): uncontrolled hypertension (≥ 160\u002F95 mmHg), congestive heart failure, uncontrolled diabetes, or extremely poor functional status rendering the patient unable to care for themselves\n* History of renal impairment, glomerulonephritis, or a single kidney, or serum creatinine level \\> 1.5 mg\u002FdL\n* Active systemic infection within 2 weeks prior to randomization (common cold excluded)\n* Current infection or history of chronic, recurrent infectious disease, or clinical test suggesting tuberculosis (including latent tuberculosis)\n* Known HIV infection, hepatitis B, or hepatitis C at screening or randomization\n* History or evidence of alcohol or drug abuse within 6 months prior to randomization\n* History of lymphoproliferative disease or known malignancy of any organ system within the past 5 years\n* Pulmonary arterial hypertension class III or IV (WHO functional classification) at screening\n* History of deep vein thrombosis at screening, or history of pulmonary embolism within 3 months prior to screening\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study (e.g., lack of compliance, difficulty in long-term follow-up)",{"count":194,"type":23},40,[196],"PHASE1","The goal of this clinical trial is to learn if allogeneic human bone marrow-derived mesenchymal stem cells (CG-BM1) are safe and show preliminary efficacy in treating patients with ankylosing spondylitis (AS). It will also explore the appropriate dose of CG-BM1.\n\nThe main questions it aims to answer are:\n\nWhat medical problems (adverse events) do participants have when taking CG-BM1? (Safety and tolerability)\n\nDoes CG-BM1 improve disease activity, pain, and function in patients with AS? (Preliminary efficacy)\n\nResearchers will compare CG-BM1 to a placebo (an inactive substance that looks like CG-BM1) in the second phase of the study to see if CG-BM1 works for AS.\n\nThis study has two phases:\n\nPhase 1 (dose-escalation): Open-label, single-arm. Participants will receive one of three escalating doses of CG-BM1 weekly for 4 weeks.\n\nPhase 2 (dose-expansion): Randomized, double-blind, placebo-controlled. Participants will receive either the recommended dose of CG-BM1 or a placebo weekly for 4 weeks, in addition to standard background therapy (celecoxib).\n\nParticipants will:\n\nReceive CG-BM1 or placebo via intravenous infusion once a week for 4 weeks\n\nVisit the clinic for follow-up assessments at Week 1, 4, 8, 12, and 24 after the first infusion\n\nUndergo physical exams, laboratory tests (blood and urine), and complete questionnaires about disease activity, pain, and function (e.g., BASDAI, VAS, ASAS response criteria)",[27],"2026-06-02",{"date":201,"type":42},"2026-06-08",{"date":203,"type":23},"2026-07-01",{"date":205,"type":23},"2027-06-01",{"name":207,"class":89},"Eighth Affiliated Hospital, Sun Yat-sen University",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":90},"100420181","testing-of-an-educational-tool-for-patients-with-melanoma-and-pre-existing-autoimmune-disease-who-are-candidates-for-immune-checkpoint-inhibitors-100420181","NCT04751396","Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors","Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers","Inclusion Criteria:\n\n* Diagnosis of melanoma\n* Diagnosis of pre-existing autoimmune disease\n\n  * Inflammatory bowel disease\n\n    * Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist\n    * For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically\n    * Treatment with aminosalicylates, corticosteroids, thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists)\n  * Rheumatoid arthritis\n\n    * Diagnosis of rheumatoid arthritis by a rheumatologist\n    * Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy\n  * Systemic lupus erythematosus\n\n    * Diagnosis of systemic lupus erythematosus by a rheumatologist\n  * Psoriasis\n\n    * Diagnosis of psoriasis by a dermatologist\n    * Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies\n  * Spondyloarthropathies\n\n    * Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis\u002Fspondylitis by a rheumatologist\n    * Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy\n* Age of 18 years or older\n* Patients whose physicians had recommended they begin using any of the currently available immune checkpoint inhibitors or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor\n* E-mail access and computer with Internet access or telephone\n* Ability to communicate in English or Spanish\n* CLINICIAN\n* Prescribed immune checkpoint inhibitors\n* Are providing care for patients with melanoma\n* In the clinics at MD Anderson",{"count":216,"type":23},125,"This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.",[27,219,220,221,222,223,224,152,225,226,227,228,229],"Autoimmune Disease","Crohn Disease","Enteropathic Arthritis","Enteropathic Spondylitis","Inflammatory Bowel Disease","Melanoma","Psoriatic Arthritis","Reactive Arthritis","Rheumatoid Arthritis","Systemic Lupus Erythematosus","Ulcerative Colitis","2026-05-18",{"date":232,"type":42},"2026-05-20",{"date":234,"type":42},"2022-04-20",{"date":236,"type":23},"2027-02-02",{"name":238,"class":89},"M.D. Anderson Cancer Center",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":62,"phases":248,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":90},"100637826","clinical-trial-study-on-the-improved-new-method-of-acupotomy-for-as-100637826","NCT07578220","Clinical Trial Study on the Improved New Method of Acupotomy for AS","Clinical Trial Study on the Improved New Method of Acupotomy for Ankylosing Spondylitis","Inclusion Criteria:\n\n1. Meeting the 1984 revised New York criteria or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis\n2. Age 18-75 years\n3. BASDAI ≥4\n4. Signed informed consent form\n\nExclusion Criteria:\n\n1. Presence of autoimmune diseases other than the studied condition\n2. Complete spinal ankylosis or spinal deformity\n3. Pregnant or lactating women\n4. Comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, malignant tumors, or coagulation disorders\n5. Patients unable to comply with data collection due to mental, linguistic, or similar factors\n6. Patients with psoriatic arthritis, reactive arthritis, or inflammatory bowel disease-associated spondyloarthritis","75 Years",{"count":125,"type":23},[249],"NA","This study employs a randomized controlled trial methodology to systematically evaluate the efficacy and safety of a modified acupotomy technique in the treatment of ankylosing spondylitis. Through ultrasound-guided localization, the operative sites are assessed to clarify the improvement effect of the modified acupotomy on disease activity in AS patients. The aim is to enhance the clinical outcomes of AS, provide evidence-based medical support for acupotomy treatment of AS, and improve the diagnosis and treatment standards for the condition.",[27],"2026-05-11",{"date":254,"type":42},"2026-05-13",{"date":256,"type":42},"2025-12-02",{"date":258,"type":23},"2029-06-30",{"name":260,"class":89},"China-Japan Friendship Hospital",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":269,"targetDuration":4,"studyType":62,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":4},"100556536","phase-2-vilamakitug-in-spondyloarthritis-placebo-controlled-investigation-for-efficacy-100556536","NCT06526377","Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy","Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Efficacy and Safety of Vilamakitug in Participants With Active Axial Spondyloarthritis","V-SPINE","Inclusion Criteria:\n\n1. Male or female aged ≥18 and ≤65 years, with body weight \\>40 kg at screening, who are willing to provide informed consent, attend all clinic visits, comply with study-related procedures and able to understand and complete study-related questionnaires.\n2. Must meet the ASAS-SPARTAN 2025 revised classification criteria for axial spondyloarthritis.\n3. Active disease at screening, defined by BASDAI ≥ 4 and ASDAS-CRP ≥ 2.1\n4. Participants should have received prior NSAIDs or have documented inadequate response to NSAIDs\n5. Participants may be biological DMARD-naïve or have documented failure of no more than 1 prior biologic DMARD (≥12 weeks)\n\nExclusion Criteria:\n\n1. History of treatment with vilamakitug\n2. Any prior exposure to \\> 1 biologic DMARD\n3. Any exposure to JAK or TYK2 inhibitors\n4. Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within a year prior to enrollment\n5. Participation in another interventional clinical study within 30 days or 5 half-lives (whichever is longer) prior to enrollment, and during the study\n6. Female participants who are pregnant or breastfeeding at screening, or who intend to become pregnant during the study or within 8 weeks after the last dose of investigational product (IP), and male participants who intend to father a child during the study or within 8 weeks after the last dose of IP.",{"count":270,"type":23},150,[64],"The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease activity, pain, function and inflammation.",[67,27,274,275],"r-axSpA","Nr-axSpA",[277],"axSpA",{"date":279,"type":42},"2026-05-14",{"date":281,"type":23},"2026-09",{"date":283,"type":23},"2028-09",{"name":285,"class":49},"XBiotech, Inc.",{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":294,"targetDuration":4,"studyType":62,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":4},"100634050","phase-1-a-phase-i-clinical-trial-for-umbilical-cord-mesenchymal-stem-cells-uc-msc-in-the-treatment-of-ankylosing-spondylitis-100634050","NCT07534644","A Phase I\u002FⅡ Clinical Trial for Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Ankylosing Spondylitis","A Phase I\u002FⅡ Clinical Trial for HS_SW01 Cells Injection in the Treatment of Ankylosing Spondylitis","HS_SW01","Inclusion Criteria:\n\n1. Age 18 to 65 years, inclusive, male or female.\n2. Voluntarily sign the informed consent form and comply with the requirements of this study protocol.\n3. Participants must have a documented diagnosis of ankylosing spondylitis (AS) based on the modified 1984 New York criteria, as follows: (a) Inflammatory back pain for ≥3 months, improving with activity but not relieved by rest;; (b) Limited spinal motion in the lumbar spine (sagittal and frontal planes); (c) chest expansion reduced relative to normal values for age and sex. (d):Sacroiliitis on imaging: bilateral grade II-IV or unilateral grade III-IV. Diagnosis of AS requires fulfillment of criterion (d) plus any one of criteria (a)-(c). The diagnosis must be confirmed at both the screening and baseline visits.\n4. Participants must have active AS at screening and baseline, defined as Ankylosing Spondylitis Disease Activity Score (ASDAS) ≥2.1, or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4.\n5. Participants must have received conventional therapy and, prior to randomization, must meet at least one of the following criteria for the following criteria, as confirmed by the investigator: (a) inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs): ≥4 weeks of continuous therapeutic-dose NSAID if one agent used; or ≥2 weeks of therapeutic-dose NSAID for each of ≥2 agents; (b) intolerance to NSAIDs: Discontinuation of NSAIDs due to treatment-related adverse events (e.g., allergic reactions, gastrointestinal symptoms or signs); the 4-week treatment duration is not required. (c) Contraindication to NSAID therapy: History of NSAID allergy, active gastrointestinal ulcer, bleeding, or other contraindications.\n6. Participants who have previously received at least two biologic disease-modifying antirheumatic drugs (bDMARDs) must have received recommended doses for at least 12 weeks prior to randomization with inadequate response, or have been intolerant to at least one bDMARD treatment (e.g., unable to continue due to adverse drug reactions, allergic reactions, or other reasons).\n7. Participants receiving concomitant oral corticosteroids or NSAIDs must be on a stable dose for at least 14 days before the baseline visit. Participants receiving conventional synthetic DMARDs (cDMARDs) must be on a stable dose for at least 28 days prior to the baseline visit.\n8. Female participants must: Be of non-childbearing potential, defined as postmenopausal for at least 1 year or surgically sterilized; OR, If of childbearing potential, agree to use strict contraceptive measures from the time of signed informed consent through at least 6 months after the last dose of study drug, and have a negative serum pregnancy test at screening.\n9. Participants must be considered in good general health based on medical history and physical examination performed at screening, as judged by the investigator.\n10. Participants must voluntarily agree to receive disease education and be willing to maintain correct posture and perform appropriate physical exercise.\n11. Participants must be willing and able to complete all study procedures and follow-up visits.\n\nExclusion Criteria:\n\n1. Hypersensitivity to any component of this product;\n2. History of significant drug abuse or alcohol dependence currently or within the past 2 years;\n3. Complete rigidity of the spine in the trial participant;\n4. Undergone bone\u002Fjoint\u002Fsynovectomy surgery within 3 months prior to screening, or planned to undergo joint or spinal surgery during the trial period;\n5. Participation in another clinical trial within 3 months prior to screening, or planned participation in another clinical trial;\n6. Severe infection indicated by clinical and radiological data; patients positive for HIV, hepatitis C, syphilis, etc.; patients with tumors or a tendency to develop tumors; patients with severe cardiac, pulmonary, hepatic, renal, hematologic, endocrine, or other systemic diseases; patients with epilepsy or psychiatric disorders;\n7. Received mesenchymal stem cell therapy within less than 3 months prior to screening;\n8. Breastfeeding women, women planning to become pregnant during the study period, or men planning to father a child;\n9. Significant laboratory abnormalities:\n\n(1) Hemoglobin \\\u003C 90 g\u002FL in males, \\\u003C 85 g\u002FL in females; (2) White blood cell count \\\u003C 3 × 10\\^9\u002FL; (3) Platelet count \\\u003C 90 × 10\\^9\u002FL; (4) AST or ALT \\> twice the upper limit of normal; (5) Other laboratory results considered markedly abnormal by the investigator; 10.Presence of active infection, including acute, chronic, or local infections (e.g., sepsis, abscess, opportunistic infection, invasive fungal infection, etc.); 11.Oral antibiotic use within 2 weeks prior to screening, or intramuscular\u002Fintravenous antibiotic treatment for infection within 4 weeks prior to screening, or a history of severe infection within 6 months prior to screening (the investigator should assess the potential risk of enrollment based on individual clinical history); 12.History of recurrent herpes zoster, history of Listeria infection, history of reticuloendothelial fungal disease, or other chronic or recurrent infections; 13.Presence of one or more of the following conditions:\n\n1. Inability to perform activities of daily living, requiring a wheelchair or bedridden due to limited mobility;\n2. Severe cardiac, pulmonary, hepatic, or renal dysfunction;\n3. Uncontrolled hypertension (150\u002F100 mmHg);\n4. History of congestive heart failure (New York Heart Association Class III\u002FIV);\n5. History of acute myocardial infarction or unstable angina within 12 months prior to screening;\n6. Cerebrovascular or cardiovascular event within 3 months prior to dosing (myocardial infarction, ischemic or hemorrhagic stroke (excluding lacunar infarction), severe arrhythmia, deep vein thrombosis, etc.);\n7. Any clinically significant respiratory disease, including but not limited to chronic obstructive pulmonary disease, asthma, interstitial pneumonia, bronchiectasis, pleural effusion;\n8. History of demyelinating disease or clinical suspicion of such disease, including but not limited to multiple sclerosis, Guillain-Barré syndrome;\n9. Unstable diabetes mellitus without stable dosing control within 4 weeks prior to screening (HbA1c \\\u003C 6.5% at screening);\n10. Other inflammatory arthritis or rheumatic diseases (other than AS) that may affect the evaluation of clinical efficacy, including but not limited to rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, gouty arthritis;\n11. Any neurological, psychiatric, or other systemic disease that may affect the evaluation of clinical efficacy;\n12. History of malignancy within the past 5 years (excluding cured non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or cervical carcinoma in situ);\n13. History of lymphoma or lymphoproliferative disease; 14.Concomitant use of the following medications:\n\n(1) Use of glucocorticoids, except for oral prednisone at a daily dose ≤ 10 mg or equivalent dose of other corticosteroids, with the dose stable for at least 4 weeks; (2) Patients who discontinued leflunomide and received cholestyramine (8 g three times daily) for 2 weeks must have a 4-week washout period before screening. Patients who discontinued leflunomide without taking cholestyramine must have a 12-week washout period from the last dose of leflunomide to screening; (3) Use of alkylating agents within 12 months prior to screening; (4) Intra-articular, intramuscular, or intravenous injection of corticosteroids within 4 weeks prior to screening; 15.The investigator considers the patient unsuitable for enrollment in this trial.",{"count":295,"type":23},18,[196,64],"The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS\\_SW01 cells injection) in patients with Ankylosing Spondylitis.\n\nParticipants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.",[27],[27,300],"MSC","2026-04-15",{"date":303,"type":42},"2026-04-20",{"date":305,"type":23},"2026-04-10",{"date":307,"type":23},"2027-12-31",{"name":309,"class":49},"Shenzhen Huishan Biotechnology Co., Ltd.",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":90},"100632215","impact-of-low-back-pain-phenotypes-on-function-and-quality-of-life-in-ankylosing-spondylitis-100632215","NCT07510789","Impact of Low Back Pain Phenotypes on Function and Quality of Life in Ankylosing Spondylitis","The Impact of Low Back Pain Phenotypes on Pain Intensity, Functional Status, and Quality of Life in Patients With Ankylosing Spondylitis","Backpaın","Inclusion Criteria:\n\n* Being over 18 years of age Voluntary participation in the study Having been diagnosed with ankylosing spondylitis\n\nExclusion Criteria:\n\n* Those under 18 years of age\n\n  * Those with major psychiatric illnesses\n  * Those with communication problems\n  * Other causes of back pain",{"count":319,"type":23},200,"This study aims to better understand different types of low back pain in patients with ankylosing spondylitis. Low back pain is a common problem in these patients and may affect daily activities and quality of life.\n\nA total of 200 patients with ankylosing spondylitis who have had low back pain for at least three months will be included in the study. Participants will be evaluated during a single visit.\n\nThe study will assess pain severity, physical function, and quality of life using standard questionnaires. It will also examine how different pain types are related to these outcomes.\n\nThe results of this study may help improve the understanding of pain in ankylosing spondylitis and support better patient management.",[27,322],"Low Back Pain",[324,325,326],"ankylosing spondylitis","types of paın","lower back pain","2026-03-30",{"date":329,"type":42},"2026-04-03",{"date":331,"type":42},"2025-12-01",{"date":333,"type":23},"2026-12-01",{"name":335,"class":336},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":99,"sex":18,"minAge":19,"maxAge":343,"enrollmentInfo":344,"targetDuration":346,"studyType":24,"phases":4,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":90},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).","99 Years",{"count":345,"type":23},5000,"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[349,350,27,225,226,351,228,352,353,354,355,356,357,358,227,359,360,361,362,363],"Rheumatic Diseases","Adult Onset Still Disease","Antiphospholipid Syndrome","Behcet Disease","Dermatomyositis","Polymyositis","Giant Cell Arteritis","Lyme Disease","Mixed Connective Tissue Disease","Polymyalgia Rheumatica","Sarcoidosis","Systemic Sclerosis","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":366,"type":42},"2026-02-13",{"date":368,"type":42},"2020-08-04",{"date":370,"type":23},"2030-06-01",{"name":372,"class":89},"Yale University",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":27,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":99,"sex":18,"minAge":380,"maxAge":381,"enrollmentInfo":382,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":384,"conditions":385,"keywords":386,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":4},"100623404","ankylosing-spondylitis-100623404","NCT07396194","Evaluation of the Relation Between Serum Interleukins 17, 38, 41, and HLA-B27 Gene Expression in Ankylosing Spondylitis Patients","Interleukins","Inclusion Criteria:\n\n* patients who are diagnosed clinically as ankylosing spondylitis (both active or stable), of either sex , who met the Assessment of Spondyloarthritis International Society (ASAS) criteria for axial spondyloarthritis.\n\nExclusion Criteria:\n\n* Patients with any autoimmune disorder, chronic illnesses as diabetes mellitus, acute and chronic infectious diseases, malignancy.","16 Years","80 Years",{"count":383,"type":23},84,"The goal of this observational study is to measure the serum level of cytokines IL-17, IL-38,IL-41, and gene expression of HLA-B27 gene in ankylosing spondylitis patients and healthy control group.\n\nThe main question it aims to answer is:\n\nDoes the disease activity, severity, serum level of cytokines (IL-17, IL-38, and IL-41) are affected by the HLA-b27 gene positivity?\n\nResearchers will compare the serum level of cytokines IL-17, IL-38,IL-41, and gene expression of HLA-B27 gene in ankylosing spondylitis patients and healthy control group to see if there significant differences in serum levels of interleukins 17, 38, 41 in AS patients and healthy control group.\n\n.",[27],[387,388,389,390],"Interleukin 17","Interleukin 38","Interleukin 41","HLA- B27 gene","2026-02-01",{"date":393,"type":42},"2026-02-09",{"date":395,"type":23},"2026-03-01",{"date":397,"type":23},"2027-03-01",{"name":399,"class":89},"Sohag University",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":99,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":90},"100622452","expression-of-tim-3-on-neutrophils-in-ankylosing-spondylitis-100622452","NCT07383805","Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis","Expression of T Cell Immunoglobulin and Mucin-domain Containing Molecule 3 (Tim-3) on Neutrophils as an Indicator to Assess Disease Activity in Ankylosing Spondylitis Patients","Adult patients (\\>18 years) diagnosed as AS according to 2009 ASAS -Classification criteria (8) Exclusion Criteria:-Age below 18 years old. Patients with other autoimmune diseases. infection (cause increase in inflammatory makers) Any patient with ferromagnetic implants or cardiac pacemaker pregnancy Uncontrolled Hypertension renal failure Chronic liver disease Malignancy Diabetes Mellitus",{"count":408,"type":23},81,"1. To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers.\n2. Association of Tim-3 with sacroiliac MRI findings and the hip inflammatory MRI scoring system (HIMRISS) .",[27,411,412],"AS","Tim3","2026-01-26",{"date":415,"type":42},"2026-02-03",{"date":417,"type":23},"2026-06-01",{"date":419,"type":23},"2029-09-01",{"name":115,"class":89},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":99,"sex":18,"minAge":19,"maxAge":246,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":4},"100618279","skin-autofluorescence-assessment-of-advanced-glycation-end-products-in-rheumatic-diseases-100618279","NCT07329556","Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases","Evaluation of Advanced Glycation End Products Accumulation in Rheumatic Diseases Using Non-Invasive Skin Autofluorescence Measurements","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Diagnosis of an inflammatory rheumatic disease (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, connective tissue diseases, Behçet disease, familial Mediterranean fever, or crystal arthropathies), confirmed by a rheumatologist\n* Healthy volunteers without a history of rheumatic or chronic inflammatory disease (for the control group)\n* Ability to undergo non-invasive skin autofluorescence measurement\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosis of diabetes mellitus (type 1 or type 2)\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Active malignancy or history of malignancy within the past 5 years\n* Presence of acute infection or acute inflammatory condition at the time of assessment\n* Secondary causes of systemic inflammation unrelated to the underlying rheumatic disease (e.g., uncontrolled endocrine disorders, chronic liver disease)\n* Use of medications known to markedly affect AGE accumulation or skin autofluorescence measurements (e.g., recent high-dose systemic glucocorticoids)\n* Pregnancy or breastfeeding\n* Presence of significant skin conditions (e.g., extensive dermatitis, scars, tattoos, or burns) at the measurement site that may interfere with skin autofluorescence assessment\n* Inability to comply with study procedures or to provide informed consent",{"count":429,"type":23},300,"Rheumatic diseases are chronic inflammatory conditions that can lead to long-term tissue damage and increased cardiovascular and metabolic risk. Advanced glycation end products (AGEs) are harmful molecules that accumulate in the body over time and are known to promote inflammation and oxidative stress. Increased AGE burden has been implicated in several chronic diseases; however, its role in rheumatic diseases has not been fully clarified.\n\nThis observational, cross-sectional study aims to evaluate the accumulation of AGEs in patients with various rheumatic diseases compared with healthy individuals. AGE levels will be assessed non-invasively using skin autofluorescence measurements.\n\nBy comparing AGE burden between patients and healthy controls, this study seeks to improve understanding of the potential role of AGEs in the pathophysiology of rheumatic diseases and to explore their usefulness as a non-invasive biomarker in clinical practice.",[432,27,225,433,434,435,436],"Rheumatoid Arthritis (RA","Reactive Arthritis (ReA)","Crystal Arthropathies","Connective Tissue Diseases","Familial Mediterranean Fever (FMF )","2026-01-08",{"date":439,"type":42},"2026-01-09",{"date":441,"type":23},"2026-01-15",{"date":443,"type":23},"2027-04-15",{"name":445,"class":336},"Bursa City Hospital",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":453,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":474},"100485642","exactech-shoulder-post-market-clinical-follow-up-study-100485642","NCT05603728","Exactech Shoulder Post Market Clinical Follow-up Study","An Open Label, Multi-Center, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcomes","Inclusion Criteria:\n\n* Patient is indicated for shoulder arthroplasty (or has previously undergone shoulder arthroplasty)\n* Patient is skeletelly mature\n* Patient is expected to survive at least 2 years beyond surgery\n* Patient is willing to participate by complying with pre- and postoperative visit requirements\n* Patient is willing and able to read and sign a study informed consent form\n\nExclusion Criteria:\n\n* Osteomyelitis of the proximal humerus or scapula; if a systemic infection or a secondary remote infection is suspected or confirmed, implantation should be delayed until infection is resolved\n* Inadequate or malformed bone that precludes adequate support or fixation of the prosthesis\n* Medial humeral bone loss resulting in compromised humeral stem fixation\n* Proximal humeral bone loss extending distal to the surgical neck where there is compromised humeral stem fixation\n* Neuromuscular disorders that do not allow control of the joint\n* Significant injury to the brachial plexus\n* Non-functional deltoid muscles\n* Patient's age, weight, or activity level would cause the surgeon to expect early failure of the system\n* The patient is unwilling or unable to comply with the post-operative care instructions\n* Alcohol, drug, or other subtance abuse\n* Any disease state that could adversaly affect the function or longevity of the implant\n* Patient is pregnant\n* Patient is a prisoner\n* Patient is contraindicated for the surgery\n* Revision cases in which a stemmed humeral component was used (Stemless Shoulder System)\n* Metal allergy or sensitivity to the implants materials (Stemless Shoulder System)\n* Acute fracture of the proximal humerus and displacement of the tuberosities, displaced three or four part fractures of the proximal humerus (hemi-arthroplasty), or acture fracture of the proximal humerus with failure of the glenohumeral joint (total anatomic shoulder arthroplasty) (Stemless Shoulder System)\n* Acute fracture of the proximal humerus in combination with degenerative diseases of the glenohumeral joint and a grossly deficient, irreparable rotator cuff resulting in superior migration of the humeral head (reverse total shoulder arthroplasty) (Stemless Shoulder System)","21 Years",{"count":455,"type":23},20000,"The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.",[458,459,460,461,27,462,227,463,464],"Osteo Arthritis Shoulders","Osteonecrosis","Rotator Cuff Tears","Rotator Cuff Tear Arthropathy","Post-traumatic Osteoarthritis","Fracture","Infections","2025-12-09",{"date":467,"type":42},"2025-12-15",{"date":469,"type":42},"2007-07-19",{"date":471,"type":23},"2031-12-31",{"name":473,"class":49},"Exactech",38,{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":62,"phases":484,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":90},"100613058","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-608-in-adult-subjects-with-active-ankylosing-spondylitisas-100613058","NCT07261644","A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis (AS)","Inclusion Criteria:\n\n1. Able to understand and comply with the protocol requirements, participate and sign the informed consent form (ICF) voluntarily;\n2. At least 18 years of age at the time of signing the ICF, with no gender restrictions;\n3. Meet the 1984 modified New York criteria for ankylosing spondylitis (AS);\n4. Have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) or have contraindications\u002Fintolerance to NSAIDs treatment;\n5. Willing to practice contraception and have no plans for pregnancy, sperm donation, or egg donation from the screening period until at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Patients with other uncontrolled active inflammatory diseases.\n2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance\n3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n4. History of cancer.\n5. Known or suspected history of immunosuppression.",{"count":483,"type":23},500,[485],"PHASE3","This study will evaluate the efficacy and safety of 608 in patients with AS.",[27],"2025-12-03",{"date":490,"type":42},"2025-12-10",{"date":492,"type":42},"2025-11-07",{"date":494,"type":23},"2027-11-18",{"name":496,"class":49},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":246,"enrollmentInfo":505,"targetDuration":4,"studyType":62,"phases":506,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":90},"100433449","phase-2-safety-and-efficacy-of-capsule-fmt-in-treatment-nave-patients-with-newly-diagnosed-chronic-inflammatory-diseases-100433449","NCT04924270","Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases","Safety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatment-naïve Patients With Newly Diagnosed Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Pulmonary Sarcoidosis, Crohn's Disease, and Ulcerative Colitis: a 52-week, Double-blind, Randomised, Placebo-controlled, Exploratory Trial","FRONT","Inclusion criteria:\n\n* Newly diagnosis of treatment-naïve RA, AS, PsA, PSar, CD, or UC.\n* Treatment-naïve which is defined as no current or previous (within 3 months) disease-modifying anti-rheumatic drugs (DMARDs) or systemic anti-inflammatory treatment including glucocorticoids.\n* Presence of CID treatment indication (no contra-indications) and patient accept to start first-line standard treatment in accordance with the national guideline for the specific diagnosis following the baseline visit.\n* Age 18 to 75 years.\n\nExclusion criteria:\n\n* Indication for biological therapy as primary therapy.\n* Celiac disease or food allergy.\n* Current cancer.\n* Hepatitis B and C, HIV, HTLV1\u002F2, and active TB or other serious chronic infections.\n* Pregnant or breastfeeding women.\n* Not wishing to participate or not suited for FMT intervention or project evaluation.",{"count":319,"type":23},[64],"PURPOSE: The main purpose is to explore clinical efficacy and safety associated with capsule FMT (cFMT) performed in newly diagnosed, untreated patients with rheumatic and gastrointestinal chronic inflammatory diseases (CIDs).\n\nDESIGN AND METHODS: In this 1:1 double-blind, placebo-controlled, randomised, 12-month exploratory trial, 200 patients with at least one of 6 different diagnoses of CIDs fulfilling the study criteria will be enrolled at time of diagnosis. The patient groups are: rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), Crohn's disease (CD), and ulcerative colitis (UC). The primary endpoint is change from baseline to eight weeks in the physical component summary (PCS) of the short form health survey (SF-36). Key secondary clinical endpoints will be evaluated at 8 weeks. Other secondary clinical endpoints will be evaluated at 52 weeks and reported in secondary papers.\n\nThe baseline visit will be performed as quickly as possible after the patient's informed consent has been obtained to ensure no unnecessary treatment delay. Stratified by CID diagnosis, patients will be randomised (1:1) to either placebo or single-donor cFMT processed from stool provided to the hospital from anonymous-to-the-patient healthy donors. The experimental intervention FMT\u002Fplacebo will be repeated once weekly the first month (i.e., each patient will receive a total of four treatments). In addition, all participants will concomitantly be offered the national guideline first-line anti-inflammatory treatment following the baseline visit.\n\nAt baseline, 8 weeks, 26 weeks, and 52 weeks a thorough clinical examination will be conducted and all relevant clinical scores for each disease entity will be registered. Patient-reported-outcomes including SF-36 and disease specific questionnaires will be collected at week 1, 2, 3, 4, 8 (primary endpoint evaluation), 26 and 52. Adverse events will be monitored through out the trial.",[227,27,225,220,229],[510,511],"Faecal microbiota transplantation","Fecal microbiota transplantation",{"date":513,"type":42},"2025-12-05",{"date":515,"type":42},"2023-12-13",{"date":307,"type":23},{"name":518,"class":89},"Odense University Hospital",{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":526,"conditions":527,"keywords":534,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":546},"100561258","a-biospecimen-collection-study-to-identify-the-targets-of-disease-reactive-t-cells-in-patients-with-autoimmune-disease-100561258","NCT06587828","A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease","Cohort Legend: Cohort 1: Inflammatory Bowel Diseases - Crohn's Disease or Ulcerative Colitis, Cohort 2: Celiac Disease, Cohort 3: Ankylosing spondylitis or non-radiographic axial spondyloarthritis (nr-axSpA), Cohort 4: Multiple Sclerosis, Cohort 5: Scleroderma, Cohort 6: Systemic Sclerosis with pulmonary involvement, Cohort 7: Other Autoimmune Disease, Cohort 8: Apparent Evolving Autoimmune Disease, Cohort 9: Frozen Cryopreserved\n\nInclusion Criteria:\n\n* Study cohorts 1,2,3,4,5,6,7,8.9: Known or suspected diagnosis, with subsequent diagnostic confirmation, of one of the following cohorts associated with the following autoimmune diseases:\n* Inflammatory Bowel Diseases - Crohn's Disease or ulcerative colitis\n* Celiac disease\n* Ankylosing spondylitis or Non radiographic axial spondyloarthritis (nr-axSpA)\n* Multiple sclerosis\n* Scleroderma\n* Systemic sclerosis with pulmonary involvement\n* Other autoimmune disease (as agreed between Investigator and Sponsor)\n* Apparent evolving autoimmune disease\n* Frozen cryopreserved\n* Age equal or greater than 18 years at time of informed consent.\n* Ability to understand and willingness to sign an informed consent document when informed consent is required by an ethical review board.\n* On disease-modifying treatments that are not known to be directly T cell toxic.\n\nSuch treatments are allowed and include:\n\n* Non-steroidal anti-inflammatory drugs including aspirin, ibuprofen, acetaminophen, celecoxib, indomethacin, diclofenac, etodolac, naproxen, meloxicam, sulindac, nabumetone amongst others.\n* Tumor necrosis factor alpha (TNF-alpha) antagonists including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and biosimilar drugs with the same generic name.\n* Interleukin-12\u002F23 antagonists including ustekinumab (Stelara) and risankizumab-rzaa (Skyrizi)\n* Alpha-4-integrin antagonists including vedolizumab (Entyvio), natalizumab (Tysabri)\n* Interleukin-17 inhibitors including secukinumab (Cosentyx), ixekizumab (Taltz)\n* Recombinant interferon beta\n* CD20 antagonists including rituximab (Rituxan), ocrelizumab (Ocrevus), ofatumumab (Kesimpta)\n* Oral fumarates including dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), monomethyl fumarate (Bafiertam)\n* Oral sphingosine 1-phosphate receptor (S1PR) modulators including fingolimod (Gilenya), siponimod (Mayzent), ozanimod (Zeposia), ponesimod (Ponvory)\n* Oral glatiramer acetate (copolymer 1; Copaxone)\n* Patient is an appropriate candidate for a procedure to obtain a biopsy, tissue samples or biologic materials during a clinically indicated procedure where it is expected that excess materials could be used for research OR\n* In the opinion of the clinical investigator, a patient is an appropriate, low-risk candidate for a research only procedure to obtain a biopsy, tissue samples or biologic materials.\n\nExclusion Criteria:\n\n* On treatment with drugs that are known to be T cell toxic and cannot be held for at least 4 weeks or longer. The following treatments are not allowed except in designated cohorts when approved by Sponsor:\n* Glucocorticoids including prednisone, methylprednisolone (Solu-medrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)\n* Sulfasalazine (Azulfidine)\n* Aminosalicylates including mesalamine\u002F mesalazine (Asacol, Pentasa).\n* Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)\n* Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)\n* CD52 inhibitors including alemtuzumab (Campath)\n* Methotrexate\n* Cladribine\n* Teriflunomide (Aubagio)\n* Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with the subject's safety.\n* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n* Patients receiving research biopsy procedures will not have a history of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine), if local anesthetic is required for the procedure or to medications used for sedation during a procedure.\n* Pregnant or nursing women are excluded because there may be unanticipated adverse events and increased risk to both mother and fetus in the setting of local anesthetic or study procedures.\n* Any other medical or psychiatric condition, which in the opinion of the patient's treating clinician, would make participation in this protocol unreasonably hazardous for the patient.",{"count":429,"type":23},"The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation. These tissues contain both cytotoxic and helper T cells that are driving their disease, and these T cells are being guided by TCRs that recognize tissue-specific targets. By collecting tissue when a patient has active inflammation, it is possible to determine which T cells are activated and undergoing clonal expansion in the patient's diseased organ. TScan has developed a genome-wide, high-throughput technology to determine the natural, physiological target of any TCR (Kula, 2019). The goal of this study is to isolate T cells from inflamed tissues and matched blood samples and\u002For matched normal tissues (for patients with inflammatory bowel diseases). T cell clones that are expanded in diseased tissues relative to blood or normal tissues will be selected and the targets of their TCRs will be defined using TScan's genome-wide, high-throughput target ID technology.\n\nThe goal of this study is to discover a collection of peptide targets, along with their associated TCRs to be developed as new tolerogenic therapies for patients with autoimmune diseases.",[528,229,529,361,27,530,531,532,533],"Autoimmune Diseases","Multiple Sclerosis","Celiac Disease","Non-radiographic Axial Spondyloarthritis (Nr-axSpA)","Crohn&Amp;#39;s Disease","Birdshot Chorioretinitis",[528,529,360,27,361,223,535,536,533],"Crohn's Disease","Non-radiographic axial spondyloarthritis (nr-axSpA)","2025-11-21",{"date":539,"type":42},"2025-11-24",{"date":541,"type":42},"2023-01-03",{"date":543,"type":23},"2027-01",{"name":545,"class":49},"TScan Therapeutics, Inc.",12,{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":411,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":62,"phases":556,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":90},"100611206","phase-3-a-study-to-evaluate-efficacy-and-safety-of-lnk01001-in-adults-with-ankylosing-spondylitis-100611206","NCT07237568","A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of LNK01001 in Adult Subjects With Active Ankylosing Spondylitis","Inclusion Criteria:\n\n* Must have a clinical diagnosis of ankylosing spondylitis (AS) and meet the modified New York Criteria for AS.\n* Participant must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥ 4 at the Screening and Baseline Visits and Must have a Total Back Pain score ≥ 4 based on a 0 - 10 numerical rating scale at the Screening and Baseline Visits.\n* Has had an inadequate response to at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or has an intolerance to or contraindication for NSAIDs as defined by the Investigator.\n\nExclusion Criteria:\n\n* Total spinal ankylosis.\n* Participants with known allergies to components or excipients of the study drug.\n* Requirement of prohibited medications during the study.\n* Participants who are pregnant, nursing, or planning a pregnancy during the study period.",{"count":555,"type":23},352,[485],"The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis.\n\nThe study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-term extension period (the Open-Label Extension Period). In the Double-Blind Period, participants will be randomized in a 1:1 ratio to receive either LNK01001 or placebo twice daily (BID). Participants in the placebo group will be switched to LNK01001 BID at Week 16 in the Open-Label Extension Period.",[27],[560,411],"LNK01001","2025-11-16",{"date":563,"type":42},"2025-11-20",{"date":565,"type":42},"2025-08-29",{"date":567,"type":23},"2027-09",{"name":569,"class":49},"Lynk Pharmaceuticals Co., Ltd",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":99,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":578,"conditions":579,"keywords":589,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":596,"leadSponsor":597,"locationsCount":4},"100607417","mass-spectrometry-based-immune-profiling-in-autoimmune-diseases-100607417","NCT07188285","Mass Spectrometry-based Immune Profiling in Autoimmune Diseases","Mass Spectrometry-based Immune Profiling in Peripheral Blood of Autoimmune Diseases","Inclusion Criteria:\n\n1. Male or female, and aged 18-70 at the time of screening interview (inclusive).\n2. The diagnosis of each disease meets the following standards - Systemic lupus erythematosus: 1997 ACR lupus classification standard\n\n   * Behcet's disease: 2014 ICBD Behcet's disease classification standard\n   * ANCA-associated vasculitis: 1990 American College of Rheumatology Classification Standard\n   * Rheumatoid arthritis: 1987 ARA classification standard\n   * Ankylosing spondylitis: new york standard revised in 1984\n   * Sjogren's syndrome: 2016 ACR\u002FEULAR Sjogren's syndrome classification standard\n   * Inflammatory myopathy: Bohan recommended criteria in 1977\n   * Systemic sclerosis: SSc standard formulated by American Rheumatology Association in 1980.\n   * Psoriatic arthritis: CASPAR standard in 2006\n   * Gouty arthritis: 1997 ACR gout classification standard\n3. Disease activity status, each disease should meet the disease activity index;\n4. Glucocorticoid (≤1mg\u002Fkg\u002Fd prednisone or other hormones with equivalent dose) was used before joining the group, and DMARDs (such as methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, leflunomide, cyclosporine, etc.) were allowed;\n5. When participating in the trial, the patient must be informed in writing and hope that the patient can abide by the requirements of the research follow-up plan and other protocols.\n\n   Exclusion Criteria:\n\n1\\. Use IVIg or cyclophosphamide within 1.2 months, use other biological agents (infliximab, adalimumab, etanercept, anakinra, etc.) within 3 months, and use rituximab within 6 months; 2.1 months after receiving high-dose glucocorticoid (\\> 1 mg\u002Fkg\u002Fd). 3. Serious complications: including heart failure (≥ NYHA III), renal insufficiency (creatinine clearance rate ≤30 ml\u002Fmin) and hepatic insufficiency (serum ALT or AST is greater than three times the normal upper limit, or total bilirubin is greater than the normal upper limit).\n\n4\\. Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve or brain diseases (including demyelinating diseases, such as multiple sclerosis).\n\n5\\. Suffering from serious infection (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or being hospitalized due to infection, or using intravenous antibiotics to treat infection 2 months before the first dose of treatment.\n\n6\\. Chest imaging showed abnormalities of malignant tumor or current active infection (including tuberculosis) within 3 months before enrollment.\n\n7\\. Infected with HIV(HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If the serum is positive, it is recommended to consult a doctor with expertise in treating HIV or hepatitis C virus infection.\n\n8\\. Any known malignant tumor or history of malignant tumor in the past 5 years. 9. Received any vaccination within 3 months before joining the group.",{"count":483,"type":23},"Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.",[580,581,582,583,584,585,27,105,586,587,588],"Systemic Lupus Erthematosus","Sjogren's Syndrome","Inflammatory Myopathies","Systemic Sclerosis (SSc)","Vasculitis","Rheumatoid Arthritis (RA)","Gouty Arthritis (GA)","Psoriatic Arthritis (PsA)","Healthy Controls",[590,591],"autoimmune diseases","mass spectrometry","2025-09-16",{"date":594,"type":42},"2025-09-23",{"date":592,"type":23},{"date":137,"type":23},{"name":598,"class":89},"Peking University People's Hospital",{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":62,"phases":608,"briefSummary":609,"conditions":610,"keywords":611,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":626},"100605773","the-impacts-of-gluten-free-diet-in-patients-with-ankylosing-spondylitis-100605773","NCT07166874","The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis","The Impacts of Gluten Free Diet on Disease Activity, Quality of Life and Intestinal Permeability in Patients Diagnosed With Ankylosing Spondylitis.","Inclusion Criteria:\n\n* diagnosis of axial SpA defined by ASAS criteria\n* Adults (aged 18-64 years)\n* stable treatment (NSAID and\u002For DMARD) for at least 3 months\n* provide written informed consent and submit to the requirements of the study\n\nExclusion Criteria:\n\n* Any diet at the time of inclusion or within 3 months prior to inclusion;\n* have a history of celiac disease;\n* have a history of Ulcerative Colitis, Crohn's Disease and Irritable Bowel Syndrom\n* patients with Type 1 and Type 2 Diabetes Mellitus\n* patients with Hashimoto Thyroiditis\n* are pregnant, breastfeeding,\n* patients who have used omega-3 and vitamins (A, C, E) regularly in the last 3 months.\n* BMI \\\u003C18,50 kg\u002Fm2\n* BMI ≥29,99 kg\u002Fm2","64 Years",{"count":125,"type":23},[249],"Subclinical intestinal inflammation and intestinal permeability have been reported in patients with ankylosing spondylitis. Gluten is one of the main triggers of zonulin releaseand gluten intake may contribute to the development of the disease by increasing intestinal permeability. This study aims to determine the impacts of a gluten-freediet on intestinal permeability, sub-clinical intestinal inflammation, disease activity, functional status and quality of life in patients with ankylosing spondylitis. The main questions it aims to answer are:\n\nDoes a gluten-free diet have an effect on disease activity and functional status in patients with ankylosing spondylitis? Does a gluten-free diet have an effect on intestinal permeability and subclinical intestinal inflammation in patients with ankylosing spondylitis? The investigators will evaluate the effects of the gluten-free diet compared to a control group.",[27],[612,613,614,324,615,616],"gluten free diet","intestinal permeability","zonulin","cytokine","BASDAI","2025-09-03",{"date":619,"type":42},"2025-09-10",{"date":621,"type":42},"2025-01-31",{"date":623,"type":23},"2026-05-31",{"name":625,"class":89},"Saglik Bilimleri Universitesi",4,{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":62,"phases":635,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":4},"100597428","effects-of-progressive-relaxation-exercises-applied-to-patients-with-ankylosing-spondylitis-on-pain-and-fatigue-levels-100597428","NCT07058363","Effects of Progressive Relaxation Exercises Applied to Patients With Ankylosing Spondylitis on Pain and Fatigue Levels","Inclusion Criteria:\n\n* Having AS diagnosis\n* Volunteering to participate in the study\n* Being over 18 years of age\n* Having internet access\n\nExclusion Criteria:\n\n* Having an orthopedic disability that prevents PGE\n* Being pregnant\n* Scoring 24 or less from the Mini Mental Test for individuals over 65 years of age\n* Wanting to leave the study\n* Having any psychiatric problems\n* Not using a communication tool that allows online interviews\n* Scoring \"0\" for pain and fatigue",{"count":634,"type":23},50,[249],"Ankylosing spondylitis (AS) is a chronic rheumatic disease with unique clinical, pathophysiological, radiographic and genetic features, the etiology of which is not known for sure, and is characterized by sacroiliac and spinal joint involvement. It is reported that this disease affects one in every 200 people, is usually diagnosed years after the onset of symptoms, and negatively affects quality of life. The prevalence of AS is between 0.2% and 1.1%, and symptoms begin before the age of 30 in approximately 80% of cases. The main complaints of patients diagnosed with AS include pain, joint stiffness, fatigue, and functional limitations of various degrees. Functional limitations resulting from inflammation and\u002For bone formations affect daily life activities, especially the person's ability to participate in leisure and domestic activities, and work productivity, and can limit social roles in the family and society. It is reported in the literature that regular PGE reduces pain and fatigue, facilitates the transition to sleep, and improves quality of life. In this context, this study aimed to evaluate the effect of PGE in reducing pain and fatigue frequently experienced by AS patients and to contribute to symptom management.",[27],"2025-06-30",{"date":640,"type":42},"2025-07-10",{"date":642,"type":23},"2025-07-15",{"date":644,"type":23},"2027-01-15",{"name":646,"class":89},"University of Gaziantep",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":99,"sex":654,"minAge":19,"maxAge":59,"enrollmentInfo":655,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":657,"conditions":658,"keywords":662,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":90},"100590474","ultrasound-assessment-of-neck-muscles-and-balance-in-male-patients-with-ankylosing-spondylitis-100590474","NCT06967883","Ultrasound Assessment of Neck Muscles and Balance in Male Patients With Ankylosing Spondylitis","The Relationship Between Ultrasonographic Measurements of Cervical Multifidus and Longus Colli Muscles and Balance in Male Patients With Ankylosing Spondylitis:Controlled Study","Inclusion Criteria:\n\n* Age between 18 and 65 years.\n* Diagnosed with Ankylosing Spondylitis according to the Modified New York Criteria (for patient group).\n* Cognitive ability sufficient to understand and follow test instructions.\n\nExclusion Criteria:\n\n* Orthopedic disorders affecting the spine or lower limbs.\n* Cardiovascular disorders.\n* Neurological disorders.\n* Visual or auditory impairments.\n* History of surgery involving the spine or lower limbs.\n* Psychiatric disorders.\n* Cognitive impairment.\n* Clinical signs or symptoms of cervical radiculopathy.","MALE",{"count":656,"type":23},76,"The aim of this study is to evaluate the relationship between ultrasonographic measurements of the cervical muscles and balance parameters in patients diagnosed with ankylosing spondylitis (AS)",[27,659,660,661],"Balance Assessment","Balance","Spondylarthropathies; Spondylitis, Ankylosing",[324,663,664],"balance","deep cervical muscles","2025-05-08",{"date":667,"type":42},"2025-05-13",{"date":669,"type":42},"2025-01-01",{"date":671,"type":23},"2025-10-01",{"name":673,"class":336},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital"]